Achieve Life Sciences, Inc. (ACHV)
After hours:
| Previous close | 5.03 |
| Open | 5.04 |
| Bid | 5.00 x 500 |
| Ask | 5.05 x 100 |
| Day's range | 4.97 - 5.12 |
| 52-week range | 3.03 - 5.98 |
| Volume | |
| Avg. volume | 125,037 |
| Market cap | 172.393M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings date | 07 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.00 |
GlobeNewswireAchieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs
SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, is pleased to announce the appointment of Dr. Mark L. Rubinstein as its new Head of Medical Affairs. Dr. Rubinstein brings more than two decades of experience in clinical medicine, scientific research, and medical affairs l
GlobeNewswireAchieve Life Sciences Announces Changes in Executive Leadership and Board of Directors
Richard Stewart reassumes role of Chief Executive Officer Thomas King appointed Executive Chairman of the Board of Directors SEATTLE and VANCOUVER, British Columbia, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Mr. Richard (Rick) Stewart, Achieve’s co-founder and current Executive Chairm
- GlobeNewswire
Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, Tuesday, August 13, 2024SEATTLE and VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced its financial results for the second quarter of 2024 and provided an update on its cytisinicline development program. Recent High
